eMedicine Specialties > Neurology > Neuro-vascular Diseases

Blood Dyscrasias and Stroke: Follow-up

Author: Souvik Sen, MD, MS, FAHA,, Associate Professor of Neurology, Founding Director of UNC Hospital Stroke Center, Director of Neurovascular Residency, Department of Neurology, University of North Carolina at Chapel Hill
Contributor Information and Disclosures

Updated: Jul 14, 2009

Follow-up

Further Outpatient Care

Patients being treated with an oral anticoagulant need to be monitored with outpatient blood testing for PT (INR). Initially, PT (INR) must be tested frequently to determine the maintenance dose (ie, daily to twice a week); once a regular maintenance dose is determined, PT (INR) may be checked monthly.

Patient Education

For excellent patient education resources, visit eMedicine's Stroke Center. Also, see eMedicine's patient education article Stroke.

Miscellaneous

Medicolegal Pitfalls

  • Supratherapeutic oral anticoagulation without monitoring can lead to intracranial and extracranial hemorrhage. Common reasons for such a state include overdosage, interaction with other drugs, and variation in dietary vitamin K. Subtherapeutic anticoagulation can lead to ischemic stroke. These potential pitfalls need to be discussed with the patient before initiating anticoagulation.
  • Another pitfall is starting a patient with a known history of life-threatening bleeding disorder and a hypercoagulable state on either an antiplatelet agent or an anticoagulant. Treatment needs to be individualized for each patient, and the benefits of any treatment need to outweigh the risks.
  • At the time of acute thrombotic events, certain coagulation parameters have acquired deficiencies (protein S and antithrombin III). In addition, patients on warfarin can have low protein C and S values, while patients on heparin have low antithrombin III values. Other conditions known to affect coagulation parameters are liver disease (protein C and S and antithrombin III), estrogens, pregnancy, and inflammatory disease (protein S).
  • More than 100 mutations account for each deficiency; thus, genetic testing is not performed in clinical practice.
  • Caution is advised to check candidates for oral anticoagulation for amyloid angiopathy with a higher propensity to bleed in the brain. MRI sequences such as gradient echo (GRE) are useful tools to detect multiple bleeds, a feature suggestive of amyloid angiopathy.
 
Acknowledgments

The authors and editors of eMedicine gratefully acknowledge the contributions of previous author Anand Vaishnav, MD to the development and writing of this article.



More on Blood Dyscrasias and Stroke

Overview: Blood Dyscrasias and Stroke
Differential Diagnoses & Workup: Blood Dyscrasias and Stroke
Treatment & Medication: Blood Dyscrasias and Stroke
Follow-up: Blood Dyscrasias and Stroke
References
[ CLOSE WINDOW ]

References

  1. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. Feb 24 1994;330(8):517-22. [Medline].

  2. Israels SJ, Seshia SS. Childhood stroke associated with protein C or S deficiency. J Pediatr. Oct 1987;111(4):562-4. [Medline].

  3. Ridker PM, Hennekens CH, Lindpaintner K. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. Apr 6 1995;332(14):912-7. [Medline].

  4. Zoller B, Dahlback B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet. 1994;343:1536-1538. [Medline].

  5. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. Feb 2006;4(2):295-306. [Medline].

  6. Adams R, McKie V, Nichols F. The use of transcranial ultrasonography to predict stroke in sickle cell disease. N Engl J Med. Feb 27 1992;326(9):605-10. [Medline].

  7. Adams RJ, McKie VC, Hsu L. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. Jul 2 1998;339(1):5-11. [Medline].

  8. Ware RE, Zimmerman SA, Schultz WH. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood. 1999;94:3022-3026. [Medline].

  9. Walters MC, Patience M, Leisenring W. Bone marrow transplantatio for sickle cell disease. NEJM. 1996;335:369-376. [Medline].

  10. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. Feb 4 2004;291(5):565-75. [Medline].

  11. Khamashta MA, Cuadrado MJ, Mujic F. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. Apr 13 1995;332(15):993-7. [Medline].

  12. Briley DP, Coull BM, Goodnight SH. Neurological disease associated with antiphospholipid antibodies. Ann Neurol. Mar 1989;25(3):221-7. [Medline].

  13. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. Sep 18 2003;349(12):1133-8. [Medline].

  14. Feldmann E, Levine SR. Cerebrovascular disease with antiphospholipid antibodies: immune mechanisms, significance, and therapeutic options. Ann Neurol. May 1995;37 Suppl 1:S114-30. [Medline].

  15. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. May 2005;3(5):848-53. [Medline].

  16. Gustafsson D, Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res. Jul 15 2003;109 Suppl 1:S9-15. [Medline].

  17. Hart RG, Kanter MC. Hematologic disorders and ischemic stroke. A selective review. Stroke. Aug 1990;21(8):1111-21. [Medline].

  18. Horn P, Bueltmann E, Buch CV. Arterio-embolic ischemic stroke in children with moyamoya disease. Childs Nerv Syst. Feb 2005;21(2):104-7. [Medline].

  19. Kannel WB. Influence of fibrinogen on cardiovascular disease. Drugs. 1997;54 Suppl 3:32-40. [Medline].

  20. Levine SR, Brey RL, Tilley BC, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. Feb 4 2004;291(5):576-84. [Medline].

  21. Martinez HR, Rangel-Guerra RA, Marfil LJ. Ischemic stroke due to deficiency of coagulation inhibitors. Report of 10 young adults. Stroke. Jan 1993;24(1):19-25. [Medline].

  22. Resch KL, Ernst E, Matrai A. Fibrinogen and viscosity as risk factors for subsequent cardiovascular events in stroke survivors. Ann Intern Med. Sep 1 1992;117(5):371-5. [Medline].

  23. Reuner KH, Ruf A, Grau A, et al. Prothrombin gene G20210-->A transition is a risk factor for cerebral venous thrombosis. Stroke. Sep 1998;29(9):1765-9. [Medline].

  24. Rothman SM. Sickle cell anemia and central nervous system infarction: a neuropathological study. Ann. Neurol. 1986;20:684-690. [Medline].

  25. [Guideline] Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke. Feb 2006;37(2):577-617. [Medline].

  26. Stein JH, McBride PE. Hyperhomocysteinemia and atherosclerotic vascular disease: pathophysiology, screening, and treatment. off. Arch Intern Med. Jun 22 1998;158(12):1301-6. [Medline].

  27. Stollberger C, Finsterer J. Search for coagulopathy does not obviate search for venous thrombosis in suspected paradoxical embolism. Stroke. Sep 2003;34(9):e146-7; author reply e146-7. [Medline].

  28. Zweifler RM. Management of acute stroke. South Med J. Apr 2003;96(4):380-5. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

hypercoagulable state, cerebrovascular event, cerebrovascular accident, coagulation disorder

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Souvik Sen, MD, MS, FAHA,, Associate Professor of Neurology, Founding Director of UNC Hospital Stroke Center, Director of Neurovascular Residency, Department of Neurology, University of North Carolina at Chapel Hill
Souvik Sen, MD, MS, FAHA, is a member of the following medical societies: American Academy of Neurology, American Heart Association, and Association for Patient Oriented Research
Disclosure: Nothing to disclose.

Medical Editor

Draga Jichici, MD, FRCP, Associate Clinical Professor, Department of Medicine, Division of Neurology and Critical Care Medicine, McMaster University, Canada
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Howard S Kirshner, MD, Professor of Neurology, Psychiatry and Hearing and Speech Sciences, Vice Chairman, Department of Neurology, Vanderbilt University School of Medicine; Director, Vanderbilt Stroke Center; Program Director, Stroke Service, Vanderbilt Stallworth Rehabilitation Hospital; Consulting Staff, Department of Neurology, Nashville Veterans Affairs Medical Center
Howard S Kirshner, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, American Heart Association, American Medical Association, American Neurological Association, American Society of Neurorehabilitation, National Stroke Association, Phi Beta Kappa, and Tennessee Medical Association
Disclosure: Boehringer Ingelheim Honoraria Speaking and teaching; BMS/Sanofi Honoraria Speaking and teaching; Novartis Honoraria Speaking and teaching

Chief Editor

Helmi L Lutsep, MD, Professor, Department of Neurology, Oregon Health & Science University; Associate Director, Oregon Stroke Center
Helmi L Lutsep, MD is a member of the following medical societies: American Academy of Neurology and American Stroke Association
Disclosure: Co-Axia Consulting fee Review panel membership; Talecris Consulting fee Review panel membership; AGA Medical Consulting fee Review panel membership; Boehringer Ingelheim Honoraria Speaking and teaching; Concentric Medical Consulting fee Review panel membership; Abbott Consulting fee Consulting; Sanofi  Consulting

RELATED EMEDICINE ARTICLES
Patient Education
 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.